Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus and MMF for Post-Grafting Immunosuppression in HCT
NCT02178683Phase 3Unknown
- Sponsor
- Colorado Blood Cancer Institute
- Start
- Nov 2010
- Primary completion
- Dec 2016
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tacrolimus, mycophenolate mofetil in graft-versus-host disease (GVHD), sponsored by Colorado Blood Cancer Institute. Status: unknown.
02
Drugs
tacrolimusmycophenolate mofetil
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT02178683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02178683.